CBD FAQ - The Largest Set of Questions and Answers 2026

CBD is sold in Poland as a cosmetic, a collectible product, and an additive to oils, with store descriptions promising sleep, calmness, and regeneration. However, readers' questions keep coming back to very basic issues: is it legal, how much to take, does it interact with medications, and does it even work? This article answers fourteen such questions plus eight short ones, with each answer leading to a specific work or recipe. Where research is lacking, we state it plainly instead of filling the gap with scientifically sounding statements. With a few popular figures, it turns out that the source says something completely different than what Polish descriptions repeat, and one of the most frequently cited bioavailability tables has no basis in any human measurement. We start with the basics, then move on to law, dosage, and interactions, and finally to indications and purchasing.

KEY INFORMATION
• The EFSA panel established a temporary safe dose of 0.0275 mg per kilogram of body weight per day in 2026, which is about 2 mg daily for a person weighing 70 kg.
• The 0.3% threshold pertains to the plant and is counted as the sum of delta-9-THC and THCA, not just THC in the finished product.
• The review by Millar et al. (2018) found the measured absolute bioavailability of CBD only for the inhalation route, around 31%.
• Bansal et al. (2023) measured in humans that a CBD-dominant extract increased exposure to omeprazole by 207%.

What is CBD and how does it differ from THC?

CBD, or cannabidiol, is one of the compounds produced by the hemp plant Cannabis sativa L. It differs from THC not in quantity, but in the way it interacts with cannabinoid receptors. The review Pertwee, British Journal of Pharmacology 2008 describes delta-9-THC as a partial agonist of CB1 and CB2 receptors, meaning it stimulates these receptors. This stimulation is responsible for the psychoactive effect.

CBD behaves differently, and here popular descriptions are usually misleading. The same review states that cannabidiol unexpectedly exhibits a high potency as an antagonist of CB1 and CB2 receptor agonists in cells and tissues expressing these receptors. In other words, CBD is not simply a weaker THC. It is a compound that acts in the opposite direction in these systems, and its affinity is described in terms of antagonism, not in terms of millions of times weaker binding.

The practical conclusion for the reader is simple and has not changed for years. CBD does not cause intoxication and does not alter perception, so it is not a substance that prohibits driving. However, this does not mean it is pharmacologically inert, as the rest of this article discusses. The basics of plant structure and other cannabinoids are covered in the entry about what CBD is.

The same review also describes a third compound worth knowing about, as it appears in descriptions of full-spectrum extracts. Delta-9-THCV behaves in laboratory conditions as a strong partial agonist of the CB2 receptor, and in tissues expressing CB1, it antagonizes agonists of that receptor. However, when administered in higher doses, it begins to act as a CB1 agonist. The conclusion is inconvenient for simple descriptions: the direction of cannabinoid action depends on the dose and the tissue, not just on its name.

The author also points out how CBD interacts with the CB2 receptor, linking it to the ability to inhibit immune cell migration triggered by stimuli. This is one of the few points where cannabidiol has a described immunological mechanism, rather than just a correlation. However, it is still an observation from cells and tissues, not a clinical outcome in patients.

How does CBD work in the body?

Here, we need to start with a correction, as the most commonly repeated explanation in Polish internet lacks a solid foundation today. The statement "CBD modulates the endocannabinoid system and inhibits the breakdown of anandamide" sounds precise, but a systematic review Ibeas Bih i wsp., Neurotherapeutics 2015 states the opposite. The authors write that CBD does not directly interact with the endocannabinoid system, except under in vitro conditions at supraphysiological concentrations.

The same review gathered over 65 distinct molecular targets described for CBD in the literature and critically assessed them. A significant portion of effects only appears at concentrations that are difficult to achieve in the body, especially given the low bioavailability of cannabidiol. After dismissing improbable targets, those related to intracellular calcium regulation remained, including the VDAC1 channel, GPR55 receptor, and CaV3-type calcium channels. The authors note that even for these, there is still no causal evidence.

The authors' conclusion is strong and worth remembering: it is very unlikely that CBD works in neurological diseases by modulating the endocannabinoid system. This does not mean that CBD does not work. It means that the mechanism used to explain its action in store descriptions is likely not the correct one.

Why is this important when purchasing? Because the argument about modulating the endocannabinoid system is sometimes used to justify two things at once: any length of use and any broad indication. Since the mechanistic explanation is questionable, both theses lose their foundation. The simpler and verifiable question remains: is there a study involving humans for my problem?

The authors also point out something that recurs later in the article. Some effects described for cannabidiol require concentrations that are difficult to achieve in the body, and its bioavailability is low. In other words, even a well-documented effect in cell culture does not automatically translate to drops under the tongue.

Is CBD legal in Poland?

Yes, and the legal basis is different from what most store descriptions state. Cannabidiol itself does not appear in the list of psychoactive substances, narcotics, or new psychoactive substances, maintained by the regulation of the Minister of Health from August 17, 2018, in its consolidated version. Dz.U. 2024 poz. 1139. The word "cannabidiol" does not appear there even once.

The 0.3% threshold applies to the plant, not the finished product, and this is the most common mistake in Polish descriptions. According to Article 4, point 5 of the Act of July 29, 2005, on counteracting drug addiction, in the consolidated text Dz.U. 2023 poz. 1939, fiber hemp refers to plants of Cannabis sativa L., in which the sum of delta-9-THC and tetrahydrocannabinolic acid in the flowering or fruiting tops, from which the resin has not been removed, does not exceed 0.3% when calculated on a dry mass basis. The sum is rounded to one decimal place.

Two clarifications worth requesting from the seller. First, the sum of delta-9-THC and THCA is measured, not just THC, so a laboratory result calculated solely from delta-9-THC does not answer the legal question. Second, the wording with 0.3% was introduced by the Act of March 24, 2022, Dz.U. 2022 poz. 763, effective from May 7, 2022. The previous threshold was 0.20% and appears in older texts as current. The national threshold corresponds to the EU threshold from Regulation 2021/2115, but it does not imply: these are two separate regulations of the same value.

It is also worth distinguishing between two substances that stand next to each other in stores. Cannabidiol is not controlled, while HHC, or hexahydrocannabinol, is a controlled substance in Poland. As of July 28, 2026, it is listed as a psychoactive substance of the second group; previously, it was in the first group. This transfer between groups, rather than legalization, means that trading and possession outside the provisions of the law remain prohibited.

Why CBD is not a dietary supplement?

Because in EU food law, CBD extracts are treated as novel food, and novel food requires authorization before being placed on the market. Until such authorization is obtained, the product cannot be sold as a dietary supplement, which is why it falls into the category of cosmetics or collectible products in Polish stores.

The safety assessment is still ongoing and received a new update in 2026. The EFSA panel on nutrition and novel food published an update on the safety of cannabidiol as a novel food (EFSA Journal, 2026). The panel searched animal and human literature up to June 2024 and found that the data gaps identified in 2022 have still not been closed. New studies have methodological limitations: non-standardized protocols, short observation times, accompanying treatments.

Three findings from this document have direct implications for consumers. Animal studies showed consistent liver toxicity, with liver mass and histopathological changes being sensitive endpoints. In humans, potential hepatotoxicity was noted, particularly with concurrent medication use. CBD crosses the placenta and accumulates systemically, and after prenatal exposure, sex-dependent neurodevelopmental effects were observed that persist for a long time.

The panel also indicated areas where data is lacking in a sense other than "they are weak." Gastrointestinal effects were reported at higher doses, neurological and psychiatric safety data were deemed insufficient, and studies on reproductive toxicity reinforced earlier concerns. Hormonal disturbances were also noted, including altered thyroid hormone levels and histopathological changes in the adrenal glands. No included study investigated immunotoxicity.

A common misunderstanding is treating sanitary notification as product approval. Notification only states that the manufacturer has reported the introduction of the preparation to the market. It does not change the status of the ingredient, is not authorization of novel food, and does not mean that anyone has assessed its effectiveness. If a seller cites notification to the sanitary inspection as proof of quality, they are referring to a document that does not state that.

How much CBD is considered safe daily today?

The answer to this question has changed and is now much more cautious than what circulates in stores. The EFSA panel established a temporary safe dose in 2026 using the benchmark dose method, based on sub-chronic studies compliant with good laboratory practice principles. After applying an uncertainty factor of 400, it arrived at 0.0275 mg per kilogram of body weight per day, which is about 2 mg daily for a person weighing 70 kg.

This number has a narrow range of application, and it is worth knowing it in its entirety. It applies only to supplemental preparations with a CBD purity of at least 98%, without nanoparticles, produced through a safe process, and with excluded genotoxicity. It is not applied at all to other forms, including full-spectrum extracts.

The panel also adds that safety cannot be established today for certain groups: for individuals under 25 years of age, for pregnant and breastfeeding women, and for those taking medications simultaneously. These are three very broad groups, and most store descriptions do not mention them.

The summary below shows the range that usually escapes discussion about dosage. The amount considered temporarily safe in a supplement and the amount administered in clinical studies differ by several orders of magnitude. This is not a contradiction: the therapeutic dose given under supervision and the dose taken uncontrolled by any individual are two different situations, assessed by different criteria. It is worth knowing, however, where your bottle lies on this scale.

What adverse effects were recorded in the studies?

The most reliable data on adverse effects come from the registration study, as they were counted systematically there. In the sample Devinsky i wsp., New England Journal of Medicine 2017 adverse effects occurring more frequently in the group with cannabidiol than in the placebo group include diarrhea, vomiting, fatigue, fever, drowsiness, and abnormal liver function test results. More individuals taking CBD than placebo also withdrew from the study.

The second frequently cited position is a case series Shannon i wsp., The Permanente Journal 2019. In this study, CBD was well tolerated by all but three patients out of 72. Rates of drowsiness at 12% or dry mouth at 11%, repeated in Polish descriptions citing this study, do not appear in its summary, and we have removed them from this article.

A signal that recurs in all sources concerns the liver. The EFSA panel in 2026 recognized liver toxicity as a consistent finding from animal studies, and in humans indicated a potential hepatotoxicity, especially in combination with medications. If you take anything regularly or have a diagnosed liver disease, this is the one piece of information from the entire article that is worth discussing with your doctor before the first drop.

It is also important to understand what the phrase "well tolerated" means in a case series. It means that the attending physician did not record a problem in the documentation, not that someone systematically asked patients about a list of symptoms. The registration study works the other way around: it collects adverse events in a set protocol and compares them with a placebo group. Therefore, the list from the work of Devinsky et al. is longer, even though it concerns the same substance.

Does CBD interact with medications?

Yes, and since 2023 this has been known from measurements in humans, not just from studies on microsomes. In the study Bansal i wsp., Clinical Pharmacology and Therapeutics 2023 eighteen healthy adults consumed in an alternating regimen a cookie without extract, a cookie with a CBD-dominant extract containing 640 mg of cannabidiol and 20 mg of delta-9-THC, or a cookie with just THC. Half an hour later, participants took a set of test medications examining individual cytochrome P450 isoenzymes.

The results are concrete and can be translated into pharmacy situations. The CBD-dominant extract increased the area under the curve of omeprazole concentration by 207%, losartan by 77%, midazolam by 56%, and caffeine by 39%. This corresponds to the inhibition of isoenzymes CYP2C19, CYP2C9, CYP3A, and CYP1A2, while CYP2D6 remained unaffected. The cookie with just THC did not inhibit any of the studied isoenzymes.

There is one more number worth knowing regarding full-spectrum preparations. The presence of CBD increased exposure to delta-9-THC by 161%, which the authors explain by the inhibition of THC clearance by CYP2C9. Thus, the same drop can raise the level of THC in the blood more than would be expected from the THC content in the product. The practical rule is this: if you are taking a medication metabolized by CYP2C19 or CYP2C9, such as a proton pump inhibitor or an anticoagulant, make the decision about CBD with your doctor or pharmacist.

Two notes about the scope of this study. The dose of 640 mg of cannabidiol is high for a consumer product, so with several milligrams daily, the scale of interactions will be smaller. However, the authors do not provide a threshold below which the interaction disappears, and pharmacokinetic modeling predicted the measured effects with an accuracy of 26% outside of caffeine. This means that the mechanism is recognized well enough to be taken seriously even at lower doses.

The practical consequence is less obvious than it seems. Staggering the timing of medication and oil intake does not eliminate isoenzyme inhibition, as inhibition concerns the enzyme, not the meeting of two molecules in the stomach. The only responsible way is to discuss the medication dose with your doctor, and for some therapies, to monitor the drug concentration in the blood.

Does CBD help with anxiety?

In experimental studies, yes, although the doses are significantly higher than those from the bottle with oil. In the study Bergamaschi i wsp., Neuropsychopharmacology 2011 twenty-four previously untreated patients with social phobia received a single dose of 600 mg of CBD or placebo one and a half hours before a simulated public speaking event. The group with cannabidiol experienced less anxiety, less cognitive impairment, and less discomfort during speech.

The second study explains why increasing the dose does not always help. Zuardi i wsp., Frontiers in Pharmacology 2017 they administered placebo, clonazepam 1 mg, or CBD at doses of 100, 300, or 900 mg to sixty healthy individuals before a real-life performance. Subjective measures of anxiety decreased in the post-performance phase only at the 300 mg dose. No effect was recorded at 100 mg and 900 mg. This is the inverted dose-effect curve that store descriptions mention, but its source is this study, not the manufacturer's guide.

The third position comes from clinical practice and has a weaker structure. In a case series, Shannon et al. (2019) reported that anxiety scores decreased in the first month for 57 out of 72 patients, or 79.2%, and persisted throughout the observation period. This is a retrospective review of documentation, without a control group, so the authors themselves conclude that controlled clinical trials are needed.

What do these three works together not say? They say nothing about the daily use of small doses over many weeks, which is exactly how consumer oils are used. The first two studies measured the effect of a single dose before a specific stressor, while the third describes treatment added to psychiatric therapy. Translating these results to several milligrams in the morning is the reader's conclusion, not the authors' conclusion.

Does CBD help with falling asleep?

The data here is clearly weaker than with anxiety, and it's worth seeing the difference in the same study. In a series of cases by Shannon et al. (2019), sleep quality improved in the first month for 48 out of 72 patients, which is 66.7%, but fluctuated in the following months. With anxiety, the improvement was maintained; with sleep, it was not. This distinction is lost in descriptions that only report the 66.7%.

It's also worth remembering where this number comes from. The review of documentation included 103 adult patients from a psychiatric clinic, and 72 were analyzed, whose main issues were anxiety or poor sleep. CBD was administered as an adjunct to existing treatment, so its effects cannot be separated from the rest of the therapy or from the natural course.

There is currently no randomized placebo-controlled study confirming the effectiveness of CBD for insomnia in adults without other diagnoses. If you are looking for sleep support, a fair piece of advice is this: treat CBD as an element you test over several weeks with a record of effects, not as a sleeping aid. A comparison of different forms and durations of action was compiled in a post. o sposobach przyjmowania.

There is another argument that calls for caution specifically regarding sleep. Drowsiness is listed in the study by Devinsky et al. as an adverse effect occurring more frequently after cannabidiol than after placebo. This means that the sedative effect is real, but it was described at therapeutic doses and as a side effect, not as a benefit for insomnia. With the dose from the bottle of oil, it is unknown whether it will even occur.

Does CBD work for epilepsy?

This is the only area where cannabidiol has full registration as a drug, and the only one where we have large randomized studies. In the trial by Devinsky et al. (2017), 120 children and young adults with Dravet syndrome and drug-resistant epilepsy received 20 mg of CBD per kilogram of body weight per day or placebo, alongside their existing antiepileptic treatment.

It is worth providing the results accurately, as they are sometimes rounded up. The median number of seizures per month decreased from 12.4 to 5.9 in the cannabidiol group, compared to a decrease from 14.9 to 14.1 in the placebo group. The adjusted median difference was 22.8 percentage points in favor of CBD. The percentage of patients with a reduction in seizures by at least half was 43% compared to 27% for placebo, but this difference did not reach statistical significance. 5% of individuals in the CBD group remained seizure-free, while no one in the placebo group did.

Two caveats close this picture. The reduction concerned seizures, while the study did not significantly reduce non-seizure events. A dose of 20 mg per kilogram means 1400 mg of cannabidiol daily for an adult weighing 70 kg, which is an amount outside the realm of consumer oils, administered under controlled liver trials.

It is also worth noting who participated in this study. These were patients with Dravet syndrome, a complex childhood epilepsy with a high mortality rate, for whom previous treatments had not worked. CBD was added to standard therapy, not used as a replacement. No element of this protocol resembles the situation of an adult buying oil for improved well-being, and this is why drug registration is not an argument for the effectiveness of a supplement.

What does CBD do on the skin?

The material in this area is laboratory-based, but specific and well-described. The work Oláh i wsp., Journal of Clinical Investigation 2014 showed in human sebocyte cultures and skin organ cultures that cannabidiol behaves like a strong sebostatic agent, meaning it inhibits sebum production.

The mechanism was established more precisely than in most works on cannabis cosmetics. CBD inhibited lipogenesis induced by arachidonic acid and the combination of linoleic acid with testosterone and limited the proliferation of sebocytes by activating TRPV4 channels. This activation disrupted the pro-lipogenic ERK1/2 MAPK pathway and reduced NRIP1 protein. Separately, the anti-inflammatory action dependent on the A2a adenosine receptor and inhibition of the NF-kB pathway were described.

What does this work not say? It does not say that CBD cream will cure acne in humans, as this was not a clinical study. The authors conclude that CBD has potential as a promising therapeutic agent in acne vulgaris, but potential is not the same as effectiveness confirmed in patients. We also did not find data on antibacterial action against acne bacteria in this work, although Polish descriptions regularly attribute this to it.

From a consumer perspective, two questions remain for the cosmetic label. How much cannabidiol is actually in the product, as concentrations in creams can be symbolic and rarely provided numerically. And whether the manufacturer promises therapeutic effects, as cosmetics cannot treat diseases, and acne vulgaris is a disease entity. A promise of a cure on the cosmetic packaging is a signal about the manufacturer, not about the ingredient.

How much CBD reaches the bloodstream from drops, and how much from a capsule?

There is currently no complete answer to this question, and that is precisely the answer. A systematic review Millar i wsp., Frontiers in Pharmacology 2018 reviewed 792 articles and found 24 that provided pharmacokinetic parameters of CBD in humans. Absolute bioavailability was measured only for the inhalation route and was about 31%. No attempts were made to establish it for any other route of administration, even though injectable forms exist.

This means that the tables with sublingual bioavailability of 13-19% and oral 6-15%, repeated in Polish descriptions, have no basis in this review. We removed them from this article and did not replace them with other numbers, as such measurements simply do not exist.

What does the review confidently state? The half-life of cannabidiol ranged from 1.4 to 10.9 hours after oral mucosal spray, from 2 to 5 days with chronic oral administration, 24 hours after intravenous administration, and 31 hours after smoking. Maximum concentration increases with dose and is reached faster via inhalation than orally. It also increases after meals and in fat-based formulations, which is the only practical tip from this review: oil taken with food yields higher concentrations than on an empty stomach.

The authors conclude the review with a note that is worth remembering when comparing products. Data is scarce, and the available ones can be inconsistent, even though cannabidiol is widely used. Without understanding bioavailability and half-life, it is difficult to speak of conscious dosing, and every table converting drops to absorption percentage is today a marketing construct, not a measurement result.

What is the difference between full spectrum, broad spectrum and isolate?

The difference lies in the composition, not in the strength of action. Isolate is purified cannabidiol without other plant components. Broad spectrum contains the remaining cannabinoids and terpenes, but with THC removed. Full spectrum retains the full plant profile along with trace THC, which is within the legal threshold for raw material.

The sales argument always sounds the same: the full profile works stronger due to the entourage effect. It is worth seeing what this thesis stands on. The work Russo, British Journal of Pharmacology 2011 is a review written by a single author, not by Russo and Mechoulam, as numerous descriptions state. The author discusses cannabis terpenoids and proposes mechanisms by which they could complement the action of cannabinoids, and finally presents methods for studying such effects in future experiments.

The closing sentence of this review is conditional and should be quoted as follows: the synergy of phytocannabinoids and terpenoids, if proven, increases the chance of creating new therapeutic products. This is a research hypothesis from 2011, not a confirmed advantage of full-spectrum preparation over isolate. When choosing between forms, therefore, consider the presence of THC and your own professional situation, not the promise of stronger action. Practical criteria for selecting the first product are compiled in a post. o pierwszym zakupie.

There is a specific reason why the choice of form has practical significance, and it stems from the work of Bansal et al. (2023). The presence of cannabidiol increased exposure to delta-9-THC by 161%, as CBD inhibits the enzyme responsible for removing orally administered THC. Therefore, a full-spectrum preparation may yield higher THC concentrations in the blood than its composition suggests. For someone subject to sobriety tests at work, this is a stronger argument than anything the entourage effect theory states.

How to read a COA certificate before purchasing?

COA, or Certificate of Analysis, is the result of testing a specific batch conducted by a laboratory. Without it, it is unknown how much cannabidiol is in the bottle, how much THC there is, or whether the raw material was pure. It is the only document that allows you to verify the manufacturer's declaration, and the only one worth asking for before purchasing.

A sensible certificate answers five questions. How much CBD and THC was measured in milligrams per gram or in percentages. Whether heavy metals were tested. Whether pesticide and solvent residues after extraction were tested. Which batch the result pertains to and what its date is. Who performed it, meaning whether the laboratory is independent of the manufacturer.

Instead of comparing bottle prices, calculate the cost per milligram of cannabidiol. A bottle with a higher price and higher concentration can be cheaper per milligram than a cheap bottle with low content, and without a certificate, none of these calculations can be done reliably.

One item from this table deserves a separate mention because it relates to the regulation described earlier. The result given solely for delta-9-THC does not answer the legal question, as the law refers to the sum of delta-9-THC and THCA. A certificate that provides one of these values and is silent about the other does not allow us to determine whether the raw material was within the threshold. This is a question worth asking the seller directly.

Frequently Asked Questions

Is CBD legal in Poland?

Yes. Cannabidiol is not listed in the controlled substances register (Journal of Laws 2024 item 1139). The 0.3% threshold pertains to the plant and is counted as the sum of delta-9-THC and THCA in flower tops, according to Article 4 point 5 of the Act on counteracting drug addiction (Journal of Laws 2023 item 1939).

How much CBD can be safely taken daily?

The EFSA panel established a temporary safe dose of 0.0275 mg per kilogram of body weight per day in 2026, which is about 2 mg daily for a person weighing 70 kg. This applies only to products with a purity of cannabidiol of at least 98%, without nanoparticles.

Does CBD cause addiction or produce a high?

CBD does not induce a high. Pertwee's review (2008) describes delta-9-THC as a partial agonist of CB1 and CB2 receptors, while cannabidiol behaves towards these receptor agonists as a strong antagonist, thus not stimulating the pathway responsible for the psychoactive effect.

Will CBD show up in a drug test?

Tests detect THC, not CBD. However, full-spectrum preparations contain trace amounts of THC, and Bansal et al. (2023) measured that the presence of CBD increases exposure to delta-9-THC by 161%. In the context of sobriety tests, a product without THC is safer.

Is it permissible to use CBD during pregnancy and breastfeeding?

No. The EFSA panel stated in 2026 that the safety of CBD cannot be established for pregnant and breastfeeding women. Cannabidiol crosses the placenta, and long-term sex-dependent neurodevelopmental effects have been observed after prenatal exposure.

Can CBD be combined with medications?

Only after consultation. Bansal et al. (2023) measured an increase in exposure to omeprazole by 207%, losartan by 77%, midazolam by 56%, and caffeine by 39% after an extract with a predominance of CBD. This corresponds to the inhibition of CYP2C19, CYP2C9, CYP3A, and CYP1A2.

How long does it take for CBD to start working?

It depends on the route of administration. Millar et al. (2018) state that the maximum concentration is reached faster via the inhalation route than orally, and the time to peak ranges from zero to four hours. A meal and fatty carrier increase the concentration.

Does CBD require a prescription?

Consumer products do not require a prescription. A registered drug with purified cannabidiol, used in drug-resistant epilepsy at doses around 20 mg per kilogram of body weight, is dispensed only by prescription and administered under liver function test control.

You can find hemp oils available in the store in the category oils. Check the content of ingredients and batch documentation on the specific product card.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-10